DANIEL CARDUCCI: Open Payments
NPI 1669812731 · FLEMINGTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,719 in 131 payments from 25 companies in 2025. Trend: 2023 $1,834 · 2024 $1,914 · 2025 $1,719
Food & beverage: $1,719
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 27 | $328 |
| AstraZeneca Pharmaceuticals LP | 9 | $196 |
| ABBVIE INC. | 15 | $183 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $180 |
| Lilly USA, LLC | 23 | $149 |
| Exact Sciences Corporation | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| GlaxoSmithKline, LLC. | 4 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Abbott Laboratories | 3 | $52 |
Products named: XIFAXAN, Wegovy, Ozempic, FARXIGA, REXULTI, MOUNJARO, QULIPTA, Cologuard Collection Kit.
Industry payments across NJ — which companies pay providers there.
